Preliposomal Annamycin Lyophilizate for Stable Liposome Reconstitution
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Annamycin, a cancer chemotherapeutic agent, presents formulation challenges due to its inherent physical properties and instability, leading to degradation and impurity formation in liposomal formulations, which are not adequately addressed by existing methods.
Innovation Solution
A method is developed to produce a preliposomal Annamycin lyophilizate with improved stability and purity by forming a lipid-containing solution with specific ratios of DMPC, DMPG, and Polysorbate 20, adjusting pH to 5.3±0.2, and lyophilizing to create a high-purity Annamycin preliposomal lyophilizate.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If liposomal formulation of Annamycin is prepared using conventional methods, then the drug can be delivered to treat cancer, but the formulation degrades and forms crystals or phase separation making it unsuitable for administration
Solution Approach 1:
The patent applies preliminary action by preparing a preliposomal lyophilizate that is stabilized in advance through specific formulation conditions (pH 4.8-5.9, specific lipid ratios, non-aqueous environment) before final liposome formation. This preliminary stabilization prevents degradation during storage and transport, and the formulation only completes liposome formation upon reconstitution with aqueous buffer immediately before administration, thus avoiding degradation that would occur in conventional ready-to-use liposomal formulations.
2Reliability
If Annamycin is formulated as liposomes to improve delivery, then cancer treatment efficacy is enhanced, but the formulation develops large liposomes or phase separation
Solution Approach 1:
The patent applies parameter changes by controlling the pH within a specific range (4.8-5.9) during the preliposomal formulation stage, which prevents premature liposome formation and ensures uniform liposome size upon reconstitution. The use of specific lipid ratios (DMPC:DMPG:Polysorbate 20) and non-aqueous solvents (t-butanol, DMSO) creates optimal conditions that maintain molecular dispersion until hydration, ensuring consistent liposome formation with appropriate size distribution for effective cancer treatment.
3Productivity
If conventional liposomal preparation methods are used, then the formulation can be produced, but purity cannot be consistently maintained and decomposition occurs
Solution Approach 1:
The patent applies the inert environment principle by using non-aqueous solvents (t-butanol, DMSO) and maintaining acidic pH conditions (4.8-5.9) that create an inert chemical environment preventing Annamycin degradation and hydrolysis. This inert formulation environment maintains high purity throughout storage and transport, and purity is only potentially compromised during the final hydration step immediately before administration, thus ensuring consistent purity maintenance throughout the drug's lifecycle.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The method ensures a consistently pure and stable Annamycin formulation, preventing decomposition and ensuring effective cancer treatment by maintaining high purity and stability, meeting regulatory standards.
Implementation Method 1
lyophilizing the lipid containing solution of Annamycin to provide a preliposomal Annamycin lyophilizate
Data Source
AI summary
Provided is a method of making a preliposomal Annamycin lyophilizate, the composition made by the method, and the use of the composition made thereby in the treatment of cancer. More specifically a method of making lyophilized Annamycin comprises the steps of: making a solution of Annamycin, one or more lipids, one or more non-ionic surfactants, and one or more solvents, sterile filtering the lipid containing solution of Annamycin; and lyophilizing the lipid containing solution of Annamycin to provide a preliposomal Annamycin lyophilizate.